Mirae Asset Global Investments
TERN

Mirae Asset Global Investments’s Terns Pharmaceuticals TERN Stock Holding History

Mirae Asset Global Investments’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,546
Closed -$292K – 1747
2026
Q1 		$292K Buy
5,546
+1,169
+27% +$48K ﹤0.01% 1020
2025
Q4 		$177K Buy
4,377
+994
+29% +$23K ﹤0.01% 1160
2025
Q3 		$25.4K Buy
3,383
+9
+0.3% +$57 ﹤0.01% 1461
2025
Q2 		$12.6K Buy
3,374
+532
+19% +$1.66K ﹤0.01% 1458
2025
Q1 		$8.3K Buy
2,842
+12
+0.4% +$49 ﹤0.01% 1486
2024
Q4 		$16.3K Buy
2,830
+285
+11% +$1.93K ﹤0.01% 1450
2024
Q3 		$21.8K Buy
2,545
+614
+32% +$5.05K ﹤0.01% 1421
2024
Q2 		$13.7K Buy
+1,931
New +$11.7K ﹤0.01% 1432
2024
Q1 		– Sell
-40,679
Closed -$264K – 2644
2023
Q4 		$264K Buy
40,679
+108
+0.3% +$571 ﹤0.01% 2247
2023
Q3 		$204K Buy
40,571
+154
+0.4% +$977 ﹤0.01% 2288
2023
Q2 		$354K Buy
+40,417
New +$471K ﹤0.01% 2108

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mirae Asset Global Investments's TERN Position: Q2 2026 in Review

Mirae Asset Global Investments sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 5,546 shares — an estimated $292K sold.

Mirae Asset Global Investments first reported a position in TERN in Q2 2023 and held it in 11 quarters. The position peaked at $354K in Q2 2023. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Mirae Asset Global Investments reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mirae Asset Global Investments sold 5,546 Terns Pharmaceuticals shares in Q2 2026, an estimated $292K.
  • Mirae Asset Global Investments first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 11 quarters.
  • Mirae Asset Global Investments's Terns Pharmaceuticals position peaked at $354K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.